Published in Blood on August 26, 2010
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol (2015) 1.17
Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program (2012) 0.92
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol (2011) 0.86
Alternative Donor Transplantation for Acute Myeloid Leukemia. J Clin Med (2015) 0.78
"No donor"? Consider a haploidentical transplant. Blood Rev (2014) 0.78
Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant (2015) 0.78
Mechanistic approaches for prevention and treatment of chronic GVHD. Blood (2016) 0.75
Halfway there: the past, present and future of haploidentical transplantation. Bone Marrow Transplant (2016) 0.75
Tregs served sunny-side up. Blood (2010) 0.75
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 16.96
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2009) 4.03
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood (2002) 3.54
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol (2002) 2.43
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood (2011) 2.35
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med (2007) 2.21
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev (2010) 2.07
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood (2012) 1.79
Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis Rheum (2006) 1.69
Real-time PCR compared to Binax NOW and cytospin-immunofluorescence for detection of influenza in hospitalized patients. J Clin Virol (2008) 1.60
Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer (2012) 1.60
Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer (2010) 1.59
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis (2006) 1.59
Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr (2008) 1.58
Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant (2011) 1.55
Differential effects of γc cytokines on postselection differentiation of CD8 thymocytes. Blood (2012) 1.46
Human cord blood CD133+ cells exacerbate ischemic acute kidney injury in mice. Nephrol Dial Transplant (2012) 1.46
Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Acta Haematol (2012) 1.43
Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer (2004) 1.43
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev (2010) 1.42
Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med (2007) 1.40
The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med (2008) 1.31
A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med (2009) 1.31
Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol (2007) 1.27
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol (2011) 1.25
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol (2010) 1.22
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther (2002) 1.16
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology (2009) 1.16
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol (2011) 1.13
2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer (2009) 1.12
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology (2010) 1.10
Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med (2003) 1.10
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer (2015) 1.10
A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev (2015) 1.10
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2008) 1.08
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res (2011) 1.07
Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med (2005) 1.07
The purified and recombinant Legionella pneumophila chaperonin alters mitochondrial trafficking and microfilament organization. Infect Immun (2009) 1.07
T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med (2005) 1.06
The signaling protein Wnt4 enhances thymopoiesis and expands multipotent hematopoietic progenitors through beta-catenin-independent signaling. Immunity (2008) 1.04
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma (2008) 1.04
P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood (2002) 1.03
ER stress affects processing of MHC class I-associated peptides. BMC Immunol (2009) 1.02
Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol (2002) 1.02
Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One (2013) 1.00
Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells (2013) 1.00
Comparison of Binax NOW and Directigen for rapid detection of influenza A and B. J Clin Virol (2004) 1.00
Health-related quality of life and coping strategies of children after treatment of a malignant bone tumor: a 5-year follow-up study. Pediatr Blood Cancer (2005) 0.99
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother (2011) 0.99
Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer (2008) 0.99
Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev (2011) 0.99
Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur J Immunol (2005) 0.99
Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS One (2011) 0.98
The Nikolas Symposia and histiocytosis. Nat Rev Cancer (2005) 0.98
High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant (2007) 0.98
Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 0.97
T regulatory cells control numbers of NK cells and CD8alpha+ immature dendritic cells in the lymph node paracortex. J Immunol (2007) 0.97
A mutant allele of the Swi/Snf member BAF250a determines the pool size of fetal liver hemopoietic stem cell populations. Blood (2010) 0.97
The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol (2011) 0.96
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2005) 0.96
Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol (2002) 0.96
Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant (2009) 0.96
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res (2012) 0.96
T-cell generation by lymph node resident progenitor cells. Blood (2005) 0.95
Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant (2006) 0.95
Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection. Virology (2007) 0.95
Detection of human metapneumovirus in clinical samples by immunofluorescence staining of shell vial centrifugation cultures prepared from three different cell lines. J Clin Microbiol (2005) 0.95
Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant (2012) 0.94
Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol (2012) 0.94
A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. Br J Haematol (2006) 0.94
Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol (2008) 0.93
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol (2013) 0.92
Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics (2010) 0.92
Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. Blood (2002) 0.92
Transcriptome sequencing of neonatal thymic epithelial cells. Sci Rep (2013) 0.92
Health-related quality of life, cognitive functioning and behaviour problems in children with Langerhans cell histiocytosis. Pediatr Blood Cancer (2009) 0.91
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res (2012) 0.91
Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J Virol (2004) 0.90
Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: is it effective? Pediatr Blood Cancer (2011) 0.90
Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood (2003) 0.90
False-positive human T-lymphotropic virus serology after intravenous immunoglobulin transfusion. CMAJ (2012) 0.90
Development and functional properties of thymic and extrathymic T lymphocytes. Crit Rev Immunol (2008) 0.90
Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res (2007) 0.90